How to Localize Labels and IFUs for Overseas Registration of Patient Monitoring Devices

How Should Labels and Instructions for Use (IFUs) Be Localized for Overseas Registration of Patient Monitoring Devices?

Localization of labels and instructions for use (IFUs) during overseas registration is not a simple translation task. It involves converting product identification, warning information, operating instructions, and clinical indications into the local language and regulatory-expected expressions based on the target country's medical device regulations. Companies must first determine whether the patient monitoring device is regulated as a medical device in the target country, clarify its classification and registration pathway, and then review existing labels, IFUs, and risk management documents from domestic (NMPA), CE, or FDA submissions to identify which items can be reused and which need to be rewritten.

Common risks include language ambiguity caused by inaccurate translation, use of non-compliant units or symbols, missing warnings, label size not meeting local requirements, and lack of review by a local representative. Companies should prepare the original label and IFU files, translation and proofreading records, comparison tables, and confirmation letters from the local representative, and submit these together with the registration application. Any post-market changes to label content must also be filed accordingly. The quality of localization directly affects the registration review timeline and post-market compliance, so it should be integrated into the project plan at an early stage rather than being addressed only after review deficiencies are raised.

For Chinese medical device manufacturers, a pragmatic approach is to first perform product classification and documentation gap assessment, then determine whether NMPA, CE, FDA, ISO 13485, or other market documentation can be reused. Registration in the target market typically affects technical files, authorized representatives, importer coordination, label language, quality system evidence, and ongoing change maintenance. If the project is driven only by “which documents to submit,” companies often face deficiencies or rework in model coverage, evidence chain consistency, labeling claims, and certificate control. AIMEILI recommends that this issue be addressed within the GHWP member countries and multi-country market access strategy, using a single set of reusable core technical files to support localization across different markets, rather than recreating documents for each country on an ad hoc basis.

Applicable Scenarios and Core Issues

Overseas registration of patient monitoring devices is a systematic project, and label and IFU localization is often the stage most likely to cause review delays. Patient monitoring devices include multi-parameter monitors, ECG monitors, pulse oximeters, blood pressure monitors, continuous temperature monitoring devices, and similar products. These devices typically have displays, electronic algorithms, and alarm functions, and fall within the category of strictly regulated medical devices.

Companies often assume that simply translating the accompanying documents into English or the local language is sufficient. In reality, target countries have specific regulatory requirements for labels and IFUs, such as the EU MDR, FDA regulations, and medical device regulations within GHWP member countries. Different markets have explicit or implicit requirements regarding language, symbols, units of measurement, warning text structure, and prohibited icons.

The core issue of localization is not whether the translation is fluent, but whether the documents can support the registration application and post-market supervision. Review authorities will check that the label and IFU are consistent with the intended purpose, performance indicators, contraindications, and adverse effects described in the technical documentation. Any ambiguity or missing information can trigger deficiency letters or even require new usability testing.

Moreover, users of patient monitoring devices may include doctors, nurses, patients, or family members, and the use environments vary significantly. The level of detail, warning reminders, and font size in the IFU will differ between home use and hospital use. Therefore, a localization plan must be embedded into the product development process before entering overseas markets, rather than waiting until registration starts to look for a translator.

Registration Judgment Logic

To determine how labels and IFUs should be localized, the first step is to confirm whether the product falls under the medical device regulatory scope in the target country. Most countries classify patient monitoring devices as medical devices, but the specific classification and level of control differ. For example, blood pressure monitors may be separately regulated as measuring instruments, while multi-parameter monitors are clearly classified as Class II or Class III devices.

After confirming the regulatory status, the next step is to determine the risk class and registration pathway. Different classifications correspond to different registration modes; for example, within the GHWP framework, some countries use a registration certificate system, while others use a notification or filing system. The pathway determines whether labels and IFUs are submitted as part of the registration dossier or as post-market surveillance documents, which in turn affects the depth and format of localization.

The applicant entity is another prerequisite variable. Overseas registration typically requires a local agent, authorized representative, or certificate holder. The local agent must review whether the labels and IFUs comply with local regulations, especially whether the warning language is appropriate. Without a reliable local agent, many detailed issues may surface during clinical use or market surveillance.

Finally, companies should assess the reusability of existing materials. NMPA product technical requirements, CE technical documentation, and FDA 510(k) labels and IFUs can all serve as a basis. However, reuse does not mean copying. It requires item-by-item verification against the target market's regulatory framework and clinical practices before performing the localization conversion.

Data and Evidence

Label and IFU localization should produce a complete language and format package, not just a final PDF. Companies should prepare the original product label and IFU, sentence-by-sentence translation draft, terminology glossaries, reference standards list, comparison table against target country regulations, and a confirmation letter from the local representative on regulatory compliance.

Reusable materials include: risk control measures related to label warnings as identified in the ISO 14971 risk management report, clauses from IEC 60601 series standards concerning marking and accompanying documents, label drawings from CE/FDA registrations, and use environment descriptions in clinical evaluations. These documents provide technical rationale and help companies quickly determine what must be translated or redrafted.

Localization must cover not only text, but also units, icons, images, and reference values. For example, the United States typically uses inches, pounds, or Fahrenheit, while GHWP member countries may require millimeters of mercury, Celsius, and specific oxygen saturation reference ranges. If the monitor display unit cannot be switched, unit explanations must be added to the label or software, otherwise it will be considered a substantive deficiency.

For home or non-professional use scenarios, the IFU should also include a plain-language version to reduce the risk of misuse. Some countries' regulatory authorities require usability descriptions for non-professional users, and may even expect user interview or cognitive test results to be submitted. These pieces of evidence should be incorporated into the localization documentation package.

Common Errors

Based on past deficiency cases observed in practice, label and IFU localization issues typically fall into the following areas. Companies should take proactive measures to avoid these errors before initiation.

• Outsourcing translation to a general translation company without setting up medical terminology review. Patient monitoring devices involve professional terms such as “arrhythmia,” “non-invasive blood pressure,” and “pulse oximetry.” Mistranslation can lead to questions from review authorities.
• Ignoring units, symbols, and display formats. For example, if the same IFU contains both “mmHg” and “kPa,” or if reference ranges do not comply with local metrology regulations, the document may be deemed unusable.
• Label content inconsistent with registration technical documents. If the intended purpose, contraindications, or target population in the IFU differ from the product technical requirements or clinical evaluation, it often results in deficiencies or even withdrawal of the application.
• Not preparing the target country language version. Some markets do not accept batch submissions where English is the primary language; a complete local language version must be provided at first submission. Submitting only an English version may be considered incomplete.
• Lack of documented local agent review. Regulators often ask, “Who confirmed the accuracy of the local language and regulatory compliance?” Without a confirmation letter or modification records from the local agent, the review trust decreases.
• Modifying labels after market approval without filing a change application. Any change to alarm thresholds, measurement ranges, environmental symbols, or symbol locations must be re-submitted according to the local change type.

Enterprise Preparation Checklist

Companies are advised to implement the following checklist to avoid discovering missing items during the supplementary review stage.

• Confirm the label and IFU language requirements in the target country's regulations, including whether the official language is required, whether English is acceptable as a substitute, and whether additional minority languages are needed.
• Establish a bilingual (Chinese-English) terminology glossary and have bilingual personnel with medical device backgrounds proofread professional terms.
• Verify the localization status of product software and display information, including units, date format, alarm text, ECG waveform labels, etc.
• Prepare vector design files of the original labels, with sufficient space to accommodate local legal requirements for minimum font size and prohibited icon placement.
• Perform a cross-reference check between each section of the IFU and the registration technical documents, ensuring that intended purpose, contraindications, and warning information are consistent.
• Obtain written confirmation from the local agent or local regulatory consultant on the label and IFU, and retain communication records.
• Plan post-market change management procedures, clearly defining which text modifications require re-registration or notification.

AIMEILI Insights

The area where companies are most likely to make misjudgments is equating localization with simple translation. What review authorities truly care about is whether the label and IFU serve to reduce risk and protect users. If there is language ambiguity—for example, translating “continuous monitoring” as “long-term monitoring”—reviewers may question the product's usability and extend the entire registration cycle.

At the project initiation stage, it is advisable to conduct a “localization gap analysis.” Do not wait until the registration document package is fully assembled. Start by comparing the CE or FDA version against the target country's language and regulations item by item, and identify what must be redone and what can be resolved by adding annotations. This analysis typically takes only three to five working days, yet can save more than two months of deficiency resolution time.

Regarding document reuse, core technical files and risk management evidence can generally be reused, but labels and IFUs must be localized market-by-market. Each country has its own clinical practices and risk control expectations; for example, Europe places more emphasis on clear warning icons, the United States stresses patient-use instructions, and some GHWP member countries require full native language versions. Reusable documents can serve as technical rationale but should not be directly submitted.

Local agents, certificate control, change management, and renewal issues should also be designed in advance. Registration certificates are typically held under the local agent's name, and the agent has an obligation to review label content. If a company only signs an agency agreement without preserving certificate control and change process decision rights, it will be very passive when trying to modify labels or add models later. It is recommended that the agency agreement clearly require the company's written consent for any change application, and set renewal deadlines.

For multi-country registration, it is even better to use a single “core clinical safety information” master version, then overlay country-specific language and regulatory differences. This approach ensures that IFUs in different countries do not contradict each other and reduces duplicate effort and deficiency risk. A typical master version includes intended purpose, contraindications, warnings, precautions, operating steps, maintenance, and troubleshooting structure. As long as structured fields are preserved, localized versions can be generated efficiently.

Common Follow-up Questions

What format of label and IFU files must be submitted for localization?

Most countries require the local-language version of labels and IFUs in PDF, along with a comparison table against the English original. Some registration systems require separate Word versions to allow reviewers to make annotations. Companies should first confirm the target country's requirements, then prepare both editable and non-editable file sets.

Can labels and IFUs from CE or FDA registration be directly copied?

It is not recommended to directly copy them. Although the technical content in CE and FDA versions may be similar, languages, symbols, and applicable regulations differ. Different markets have different requirements for warning signs, contraindication phrasing, and unit systems. Local review authorities will require submission in the target language and will examine differences from the Chinese or English versions. It is advisable to use existing documents as a basis for localization, rather than simply changing the file extension.

Should localization be performed by the manufacturer or outsourced to the local agent?

It is recommended that the manufacturer lead technical content and the local agent handle regulatory compliance review. The manufacturer understands the product risks and operational logic best and can ensure accurate translation of technical content. The local agent is familiar with the local language, review habits, and real-world use environments, and can identify subtle expression issues that may otherwise be overlooked. A combination of both is the most reliable approach.

Source and Applicability

This article is compiled based on AIMEILI's registration practice database, medical device international registration knowledge base, and publicly available regulatory information. Specific projects should be based on the latest requirements of the target country's regulatory authority and the actual product documentation. The content is intended for preliminary understanding, document preparation, and project planning, and does not replace the official requirements of the target country's regulator, testing conclusions, or legal advice.